Quetmolimab: A Deep Dive into KANAb 001 and E-6011 The agent, E-6011, is a novel treatment targeting the PD-1 receptor. Early study data from these programs, KANAb 001 and E-6011, suggest significant response in https://www.targetmol.com/compound/quetmolimab